Lena Specht
YOU?
Author Swipe
View article: Efficacy and toxicity of hypofractionated radiation therapy for patients with hematologic malignancies: A COVID-era ILROG collaborative report
Efficacy and toxicity of hypofractionated radiation therapy for patients with hematologic malignancies: A COVID-era ILROG collaborative report Open
Treatment of hematologic malignancies patients with hRT was generally well tolerated with few unexpected toxicities. These data provide guidance for emergencies, and hRT may be useful and could be considered even in routine settings, espec…
View article: Late Cardiac Toxicity After Anthracyclines and Radiotherapy for Lymphoma—A Regression Analysis of Dose‐Response
Late Cardiac Toxicity After Anthracyclines and Radiotherapy for Lymphoma—A Regression Analysis of Dose‐Response Open
Late cardiac toxicity after radiation therapy and/or systemic therapy with anthracyclines for lymphomas is a serious concern. To estimate the risks with different treatment combinations, reliable estimates of the dose‐response relationship…
View article: Total skin electron beam therapy
Total skin electron beam therapy Open
Primary cutaneous lymphomas are highly radiosensitive. X-rays work well for localized cutaneous lymphomas. However, if disseminated in the skin and covering larger areas, as is commonly the case with the most common type, mycosis fungoides…
View article: Risk Stratification for Trial Enrichment Considering Loco‐Regional Failure in Head and Neck Cancer: <scp>UICC8</scp> Versus Purpose‐Built Failure‐Type Specific Risk Prediction Model
Risk Stratification for Trial Enrichment Considering Loco‐Regional Failure in Head and Neck Cancer: <span>UICC8</span> Versus Purpose‐Built Failure‐Type Specific Risk Prediction Model Open
Background A previously published failure‐type specific risk model showed good performance in the original cohort. Aim: to validate the model and separate patients with high‐ and low‐risk loco‐regional failure (LRF). Goal: to identify pati…
View article: Breaking Down the Barriers for Patients With Cutaneous T-Cell Lymphoma: Current Controversies and Challenges for Radiation Oncologists in 2024
Breaking Down the Barriers for Patients With Cutaneous T-Cell Lymphoma: Current Controversies and Challenges for Radiation Oncologists in 2024 Open
Cutaneous T-cell lymphomas (CTCL) are a rare collection of diseases, frequently associated with diagnostic challenges and complex management dilemmas. The multidisciplinary team is vital for accurate clinico-pathological diagnoses and for …
View article: Cardiac dose-volume analysis of 9,411 patients with registry data for cardiovascular disease and overall survival.
Cardiac dose-volume analysis of 9,411 patients with registry data for cardiovascular disease and overall survival. Open
Background and purpose Radiation therapy (RT) to the thorax poses risks of radiation-induced cardiotoxicity, potentially increasing cardiovascular diseases (CVD) incidence. Advances in RT strive to minimize these risks by reducing heart ra…
View article: Late effects following HSCT for childhood ALL: A national single‐center study using three different modalities of delivery of total body irradiation
Late effects following HSCT for childhood ALL: A national single‐center study using three different modalities of delivery of total body irradiation Open
Background Total body irradiation (TBI) is a pivotal part of conditioning prior to hematopoietic stem cell transplantation (HSCT) for childhood acute lymphoblastic leukemia (ALL), yet evidence is sparse regarding the effect of TBI delivery…
View article: Primary central nervous system lymphomas: EHA–ESMO Clinical Practice Guideline for diagnosis, treatment and follow‐up
Primary central nervous system lymphomas: EHA–ESMO Clinical Practice Guideline for diagnosis, treatment and follow‐up Open
Highlights This EHA‐ESMO Clinical Practice Guideline provides key recommendations for managing primary DLBCL of the CNS. The guideline covers clinical, imaging and pathological diagnosis, staging and risk assessment, treatment and follow‐u…
View article: Late effects following HSCT childhood ALL: a national single center study using 3 different modalities of delivery of total body irradiation
Late effects following HSCT childhood ALL: a national single center study using 3 different modalities of delivery of total body irradiation Open
Background: Total body irradiation (TBI) is a pivotal part of conditioning prior to hematopoietic stem cell transplantation (HSCT) for childhood acute lymphoblastic leukemia (ALL), yet evidence regarding the effect of TBI delivery techniqu…
View article: Pulmonary diseases in patients with classical Hodgkin lymphoma relative to a matched background population: A Danish national cohort study
Pulmonary diseases in patients with classical Hodgkin lymphoma relative to a matched background population: A Danish national cohort study Open
Summary Late toxicities can impact survivorship in patients with classical Hodgkin lymphoma (cHL) with pulmonary toxicity after bleomycin‐containing chemotherapy being a concern. The incidence of pulmonary diseases was examined in this Dan…
View article: Time trends in cardiac doses in 10,000 patients receiving curative thoracic radiation therapy between 2009 and 2020
Time trends in cardiac doses in 10,000 patients receiving curative thoracic radiation therapy between 2009 and 2020 Open
Background and purpose In the last 20 years, it has become well-documented that incidental cardiac exposure to ionizing radiation is associated with a clinically relevant increased risk of cardiovascular morbidity. In parallel, radiation t…
View article: Long-Term Follow-Up of the Response-Adapted Intergroup EORTC/LYSA/FIL H10 Trial for Localized Hodgkin Lymphoma
Long-Term Follow-Up of the Response-Adapted Intergroup EORTC/LYSA/FIL H10 Trial for Localized Hodgkin Lymphoma Open
Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. …
View article: Prediction of post-radiotherapy recurrence volumes in head and neck squamous cell carcinoma using 3D U-Net segmentation
Prediction of post-radiotherapy recurrence volumes in head and neck squamous cell carcinoma using 3D U-Net segmentation Open
Locoregional recurrences (LRR) are still a frequent site of treatment failure for head and neck squamous cell carcinoma (HNSCC) patients. Identification of high risk subvolumes based on pretreatment imaging is key to biologically targeted …
View article: A systematic review on clinical adaptive radiotherapy for head and neck cancer
A systematic review on clinical adaptive radiotherapy for head and neck cancer Open
The literature on clinical ART in HNC is limited. ART is associated with small reductions in doses to organs at risk, but the influence on toxicity and disease control is uncertain. There is a clear need for larger, prospective trials with…
View article: The potential for local ablative therapy of oligometastases in head and neck squamous cell carcinoma: a real-world data analysis
The potential for local ablative therapy of oligometastases in head and neck squamous cell carcinoma: a real-world data analysis Open
Patients with head and neck squamous cell carcinoma (HNSCC) who develop post-treatment distant metastases (DM) have a poor prognosis and few treatment options. DMs from HNSCC are rare compared to other solid tumors, occurring in 5%–20% of …
View article: A comparison of loco-regional relapse pattern in HPV positive vs negative oropharyngeal cancers following radiotherapy; relation to pretreatment FDG-PET and radiotherapy target volumes
A comparison of loco-regional relapse pattern in HPV positive vs negative oropharyngeal cancers following radiotherapy; relation to pretreatment FDG-PET and radiotherapy target volumes Open
There were no signs of difference in loco-regional relapse pattern between HPV positive and HPV negative patients. In agreement with previous findings, GTV-PET was the most frequent RT target volume of relapse.
View article: Personalised therapy in follicular lymphoma – is the dial turning?
Personalised therapy in follicular lymphoma – is the dial turning? Open
Follicular lymphoma is the most common indolent lymphoma accounting for approximately 20%–25% of all new non‐Hodgkin lymphoma diagnoses in western countries. Whilst outcomes are mostly favorable, the spectrum of clinical phenotypes include…
View article: Career development: A balance of opportunities and choices
Career development: A balance of opportunities and choices Open
Persisting disparities between the sexes in academic medicine have been the experience of many and have been well-documented objectively in recent years both by female and male authors.1-4 Although the situation is undoubtedly improving, t…
View article: Efficacy and toxicity of hypofractionated radiation therapy for patients with hematologic malignancies: update on a COVID era ILROG collaborative report
Efficacy and toxicity of hypofractionated radiation therapy for patients with hematologic malignancies: update on a COVID era ILROG collaborative report Open
Purpose/Objectives: During COVID19, shorter radiation therapy (RT) courses were considered to minimize patient exposure, ensure staff safety, and conserve healthcare resources. Due to concerns with the safety of systemic therapy, RT demand…
View article: EARLY FDG‐PET ADAPTED TREATMENT OF LIMITED STAGE HODGKIN LYMPHOMA (HL): 10Y LONG TERM FOLLOW‐UP ANALYSIS OF THE RANDOMIZED INTERGROUP EORTC/LYSA/FIL H10 TRIAL
EARLY FDG‐PET ADAPTED TREATMENT OF LIMITED STAGE HODGKIN LYMPHOMA (HL): 10Y LONG TERM FOLLOW‐UP ANALYSIS OF THE RANDOMIZED INTERGROUP EORTC/LYSA/FIL H10 TRIAL Open
Background: Though the outcome of patients with stage I/II HL is excellent with standard combined chemo- and radiotherapy, the H10 trial assessed the possibility of improving tumor control by treatment intensification in early (i.e., after…
View article: THE PROGNOSTIC IMPACT OF CLINICAL FACTORS AND IMMUNOARCHITECTURAL PATTERNS FOR NODULAR LYMPHOCYTE‐PREDOMINANT HODGKIN LYMPHOMA: AN INTERNATIONAL STUDY BY GLOW
THE PROGNOSTIC IMPACT OF CLINICAL FACTORS AND IMMUNOARCHITECTURAL PATTERNS FOR NODULAR LYMPHOCYTE‐PREDOMINANT HODGKIN LYMPHOMA: AN INTERNATIONAL STUDY BY GLOW Open
Introduction: Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) is a rare entity. Studies evaluating outcomes for patients of all ages with scoring of immunoarchitectural patterns (IAPs) are needed to inform optimal management. We so…
View article: MR‐GUIDED ADAPTIVE RADIOTHERAPY FOR GASTRIC LYMPHOMA, PRELIMINARY RESULTS FROM ONGOING STUDY
MR‐GUIDED ADAPTIVE RADIOTHERAPY FOR GASTRIC LYMPHOMA, PRELIMINARY RESULTS FROM ONGOING STUDY Open
Radiotherapy is a curative treatment in indolent lymphoma and an important part of the combined treatment for aggressive gastric lymphoma. New technologies have changed the options for normal tissue sparing with same target dose coverage s…
View article: Reappraisal of the role of radiation therapy in lymphoma treatment
Reappraisal of the role of radiation therapy in lymphoma treatment Open
Radiation therapy (RT) for lymphomas has improved dramatically with modern imaging and treatment techniques, encompassing only the necessary volume with minimal doses to normal structures. Prescribed radiation doses are reduced, and fracti…
View article: Data from Long-term Safety of Treatment with Autologous Mesenchymal Stem Cells in Patients with Radiation-Induced Xerostomia: Primary Results of the MESRIX Phase I/II Randomized Trial
Data from Long-term Safety of Treatment with Autologous Mesenchymal Stem Cells in Patients with Radiation-Induced Xerostomia: Primary Results of the MESRIX Phase I/II Randomized Trial Open
Purpose:Mesenchymal stem/stromal cell therapy may reduce radiation-induced xerostomia. We investigated the long-term safety of autologous adipose tissue-derived mesenchymal stem/stromal cell (ASC) injections into the submandibular glands.E…
View article: Supplementary Data from Long-term Safety of Treatment with Autologous Mesenchymal Stem Cells in Patients with Radiation-Induced Xerostomia: Primary Results of the MESRIX Phase I/II Randomized Trial
Supplementary Data from Long-term Safety of Treatment with Autologous Mesenchymal Stem Cells in Patients with Radiation-Induced Xerostomia: Primary Results of the MESRIX Phase I/II Randomized Trial Open
Supplementary Data from Long-term Safety of Treatment with Autologous Mesenchymal Stem Cells in Patients with Radiation-Induced Xerostomia: Primary Results of the MESRIX Phase I/II Randomized Trial